Semaglutide, the active ingredient in brand names like Ozempic® and Wegovy® has quickly become one of the most widely prescribed medications for weight loss and type 2 diabetes management. Semaglutide has helped many people achieve lasting health … Read more
Planning your 2025 weight loss journey? Depending on your plan, FSA and/or HSA funds may be eligible to use with prescription weight loss medications. If not, you still have flexible ways to manage costs. Whether you’re considering … Read more
For those considering Wegovy® (semaglutide), Ozempic® (semaglutide), or compounded semaglutide for weight loss or as a treatment option for type 2 diabetes management, gaining clarity on the financial implications is important. This overview examines costs with insurance … Read more
If you’re experiencing fatigue while taking Ozempic® (semaglutide), Wegovy®(semaglutide), or compounded semaglutide, you’re not alone. Learn how to manage this common side effect and maintain your energy levels. Fortunately, this fatigue is often temporary and manageable with … Read more
FDA notice on Zepbound™/Mounjaro® shortage: On December 19th, 2024, the U.S. Food and Drug Administration determined that the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has ended. Patients may continue receiving essential copies through … Read more
FDA notice on Zepbound®/Mounjaro® shortage: On October 2, 2024, the U.S. Food and Drug Administration determined that the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, had ended. (Read more) Schedule a visit with an Ivim … Read more
FDA notice on Wegovy®/Ozempic® shortage: On February 21st, 2025, the U.S. Food and Drug Administration determined that the shortage of semaglutide injection, a glucagon-like peptide 1 (GLP-1) medication, has ended. Patients may continue receiving essential copies through … Read more
FDA notice on Zepbound®/Mounjaro® shortage: On October 2, 2024, the U.S. Food and Drug Administration determined that the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, had ended. (Read more) Schedule a visit with an Ivim … Read more
